Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

TWYMEEG® sales continue to increase in Japan for the last quarter (July-September) by 5% over the prior quarter and by 23% over the 3rd quarter 2023 Poxel expects TWYMEEG® net sales in Japan in the near term to…

Read this Press Release: Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

Poxel Announces Availability of the 2023 Universal Registration Document

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic…

Read this Press Release: Poxel Announces Availability of the 2023 Universal Registration Document

Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update

Agreement with OrbiMed to monetize a portion of TWYMEEG® Royalties for USD 50 million in the form of bonds issuance In return OrbiMed to obtain the royalties received by Poxel from sales by Sumitomo Pharma of…

Read this Press Release: Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership